We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Kiniksa

News List

Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis firstwordpharma
June 09, 2021
Kiniksa Pharmaceuticals, Ltd. today announced that the U.S Patent and Trademark Office issued a patent covering methods of using ARCALYST® (rilonacept) in the treatment of recurrent pericarditis.
FDA nod for Kiniksa’s Arcalyst in recurrent pericarditis pharmatimes
March 22, 2021
The US Food and Drug Administration (FDA) has approved Kiniksa Pharmaceuticals’ interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) inhibitor Arcalyst (rilonacept) for the treatment of recurrent pericarditis and reduction in risk of recurrence ...
Kiniksa and Scholar Rock gun for $175M IPOs as 2 other biotechs fiercebiotech
May 02, 2018
It was something of an up-and-down week for IPOs: Two biotechs, Alzheimer’s focused Alzheon and brittle bone drug company Mereo BioPharma pulled their ...